Search

Raymond L Dagnino

from El Cajon, CA
Age ~63
Get Report
Also known as:
Raymond J Dagnino, Raymond T Dagnino, Ray L Dagnino
Phone and address:
1933 Hidden Mesa Rd, El Cajon, CA 92019
(619) 442-3639
Related to:
Helen T Dagnino, 63Harold D Treadway, 94Enemirta C Treadway, 88Robert H Dagnino, 32Andrew J Dagnin, 28
Connected to:
Alma D Dagnino, 57Benny Dagnino, 68Martha E Dagnino, 63Steven L Dagnino, 76Aichatou Dagnoko, 33Douglas J Dagnon, 60Joyce A Dagnon, 64Keimonte D Dago, 33Alberta J Dagon, 104

Raymond Dagnino Phones & Addresses

  • 1933 Hidden Mesa Rd, El Cajon, CA 92019 (619) 442-3639
  • San Clemente, CA
  • 11365 Surco Dr, San Diego, CA 92126 (858) 549-4909
  • 1933 Hidden Mesa Rd, El Cajon, CA 92019 (619) 840-7151

Work

Position: Administrative Support Occupations, Including Clerical Occupations

Education

Degree: High school graduate or higher

Emails

r***[email protected]

Resumes

Resumes

Raymond Dagnino Photo 1

Vice President Of Business Development

View page
Location:
1933 Hidden Mesa Rd, El Cajon, CA 92019
Industry:
Pharmaceuticals
Work:
Agno Pharma Jul 2008 - Jul 2010
Senior Director of Business Development
Agno Pharma Jul 2008 - Jul 2010
Vice President of Business Development
Neurocrine Biosciences Nov 2002 - Jan 2008
Development Sourcing Specialist
Neurocrine Biosciences 2000 - 2007
Associate Director Development Sourcing
Education:
San Diego State University 1983 - 1986
Bachelors, Bachelor of Science, Chemistry
Skills:
Drug Development
Chemistry
Technology Transfer
Cro
Product Development
R&D
Medicinal Chemistry
Analytical Chemistry
Interests:
Environment
Poverty Alleviation
Science and Technology
Disaster and Humanitarian Relief
Human Rights
Languages:
Spanish
Raymond Dagnino Photo 2

Senior Manager Development Sourcing At Neurocrine Biosciences Inc.

View page
Location:
Greater San Diego Area
Industry:
Pharmaceuticals

Publications

Us Patents

Efficient Methods For The Preparation Of Rhinovirus Protease Inhibitors, Key Intermediates And A Continuous Membrane Reactor Useful For Preparing The Same

View page
US Patent:
20030064429, Apr 3, 2003
Filed:
Jul 25, 2002
Appl. No.:
10/201944
Inventors:
Junhua Tao - San Diego CA, US
Srinivasan Babu - San Diego CA, US
Raymond Dagnino - El Cajon CA, US
Qingping Tian - San Diego CA, US
Travis Remarchuk - Irvine CA, US
Kevin McGee - San Diego CA, US
Naresh Nayyar - San Diego CA, US
Terence Moran - San Diego CA, US
Assignee:
Agouron Pharmaceuticals, Inc.
International Classification:
C12P033/02
C12N009/48
C12N009/50
US Classification:
435/061000, 435/212000, 435/219000
Abstract:
Efficient synthetic routes for the preparation of rhinovirus protease inhibitors of formula I, key intermediates useful in those synthetic routes, as well as a continuous membrane reactor useful for those synthetic routes. These compounds of formula I, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.

Metalloproteinase Inhibitors, Pharmaceutical Compositions Containing Them And Their Pharmaceutical Uses, And Methods And Intermediates Useful For Their Preparation

View page
US Patent:
20030130506, Jul 10, 2003
Filed:
Nov 18, 2002
Appl. No.:
10/298842
Inventors:
Scott Zook - Del Mar CA, US
Raymond Dagnino - San Diego CA, US
Michael Deason - Poway CA, US
Steven Bender - Oceanside CA, US
Michael Melnick - San Diego CA, US
Assignee:
Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07D417/02
C07D213/63
US Classification:
544/060000, 546/014000, 546/290000
Abstract:
The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Metalloproteinase Inhibitors And Intermediates Useful For Their Preparation

View page
US Patent:
61537578, Nov 28, 2000
Filed:
Jun 29, 1998
Appl. No.:
9/011971
Inventors:
Scott E. Zook - Del Mar CA
Raymond Dagnino - San Diego CA
Michael E. Deason - Poway CA
Steven L. Bender - Oceanside CA
Michael J. Melnick - San Diego CA
Assignee:
Agouron Pharmaceuticals, Inc. - La Jolla CA
International Classification:
C07D21368
C07D21370
US Classification:
546301
Abstract:
The invention relates to compounds of formula (1) ##STR1## wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Methods Of Synthesis Of Peptidyl Argininals

View page
US Patent:
55147771, May 7, 1996
Filed:
Jun 17, 1994
Appl. No.:
8/261380
Inventors:
Thomas R. Webb - Encinitas CA
John E. Reiner - San Diego CA
Susan Y. Tamura - San Diego CA
William C. Ripka - San Diego CA
Raymond Dagnino - San Diego CA
Assignee:
Corvas International, Inc. - San Diego CA
International Classification:
C07K 500
C07K 700
C07K 1700
C07D21122
US Classification:
530331
Abstract:
This invention provides solution-phase methods for the synthesis of peptidyl argininals and to novel reagents useful therein.

Method Of Synthesis Of Peptidyl Aldehydes

View page
US Patent:
57314136, Mar 24, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/482281
Inventors:
Thomas Roy Webb - Encinitas CA
John Eugene Reiner - San Diego CA
Susan Yoshiko Tamura - San Diego CA
William Charles Ripka - San Diego CA
Raymond Dagnino - San Diego CA
Ruth Foelsche Nutt - San Diego CA
Assignee:
Corvas International, Inc. - San Diego CA
International Classification:
A61K 3800
C07K 500
US Classification:
530331
Abstract:
This invention provides solution-phase and solid-phase methods for the synthesis of peptidyl argininals and to �novel! reagents useful therein.

Efficient Synthetic Routes For The Preparation Of Rhinovirus Protease Inhibitors And Key Intermediates

View page
US Patent:
20020133020, Sep 19, 2002
Filed:
Oct 30, 2001
Appl. No.:
09/984555
Inventors:
Qingping Tian - San Diego CA, US
Naresh Nayyar - San Diego CA, US
Srinivasan Babu - San Diego CA, US
Junhua Tao - San Diego CA, US
Terence Moran - San Diego CA, US
Raymond Dagnino - El Cajon CA, US
Lennert Mitchell - Hemet CA, US
Travis Remarchuk - Irvine CA, US
Michael Melnick - Ann Arbor MI, US
Steven Bender - Oceanside CA, US
Assignee:
Agouron Pharmaceuticals, Inc.
International Classification:
C07D413/02
US Classification:
548/229000
Abstract:
Efficient synthetic routes for the preparation of rhinovirus protease inhibitors of formula I, as well as key intermediates useful in those synthetic routes. These compounds of formula I, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.
Control profile
Raymond L Dagnino from El Cajon, CA, age ~63 Get Report